Mylan NV, manufacturer of the lifesaving allergy medication EpiPen, has agreed to pay $30 million in fines to settle charges by the U.S. Securities and Exchange Commission that the company misled investors by making false accounting statements and disclosures about a Justice Department probe into whether the company had overcharged Medicaid by hundreds of millions of dollars, the SEC announced Friday.

Without admitting or denying the SEC’s allegations, Mylan, headquartered in the Netherlands with U.S. operations based in Canonsburg, Pennsylvania, agreed to the entry of a final judgment ordering a $30 million penalty and permanently enjoining it from violating sections of the Securities Act of 1933 and Securities Exchange Act of 1934.